TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Onconetix ( (ONCO) ) has issued an announcement.
On September 17, 2025, Onconetix‘s subsidiary, Proteomedix AG, entered a licensing agreement with Immunovia, a Swedish pancreatic cancer diagnostics company. Under this agreement, Proteomedix will supply Immunovia with master cell lines and a license to intellectual property for manufacturing reagents used in the PancreaSure test. In return, Immunovia will pay Proteomedix $700,000 over two years and a 3% royalty on net sales of PancreaSure and related products from 2026 to 2032. This agreement allows Immunovia to produce key reagents for PancreaSure independently, potentially enhancing early detection of pancreatic cancer and improving patient outcomes.
Spark’s Take on ONCO Stock
According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.
Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.
To see Spark’s full report on ONCO stock, click here.
More about Onconetix
Onconetix, Inc. is a commercial stage biotechnology company focused on research, development, and commercialization of innovative solutions for men’s health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union under the IVDR.
Average Trading Volume: 615,547
Technical Sentiment Signal: Sell
Current Market Cap: $4.59M
See more data about ONCO stock on TipRanks’ Stock Analysis page.